Chinese scientists have established a new technology platform that reveals how genetic mutations in tumors reshape the microenvironment and modulate immune responses, a discovery that could explain why modern cancer treatments often fail in patients whose cancers have spread.
The study, published in the journal Cell on Thursday, was jointly conducted by a Shanghai-based team from the Center for Excellence in Molecular Cell Science at the Chinese Academy of Sciences, in collaboration with teams from Shanghai Jiao Tong University, and Guangzhou Laboratory.
Using the new technology platform called CLIM-TIME (CRISPR-Laser-captured microdissection Integration Mapping of Tumor Immune Microenvironment), the researchers analyzed 391 common tumor suppressor genes to see how they reshape the tumor microenvironment — the biological neighborhood surrounding a tumor, and classified them into seven distinct subtypes.
The researchers found that the loss of certain tumor suppressor genes — genes that normally prevent cancer growth — triggers a massive buildup of collagen. This excess collagen makes the tumor structure so dense that it acts like a wall, preventing T cells — the body's natural "assassin" cells — from reaching and killing the cancer.
"It acts like a spider weaving a web. This web not only supports itself but also recruits and reshapes other normal cells from the body into accomplices that help shape this suppressive environment, blocking T cells' entry," said Wang Guangchuan, researcher at the Center for Excellence in Molecular Cell Science.
The team identified a specific molecule called LOXL2 as the architect of this barrier. In tests on mice, researchers found that by blocking LOXL2, they could dissolve the collagen wall. This allowed T cells to penetrate the tumor and significantly boosted the power of immunotherapy drugs.
We combined this with current CAR-T cell therapy. One major issue with CAR-T is that it can't enter solid tumors. When treating human tumors with CAR-T, if we use a small molecule to target this protein we've identified, it could significantly improve CAR-T treatment outcomes. Of course, when it comes to clinical application, we still need to evaluate its safety [and other indicators]," Wang said.
CAR-T is an immunotherapy involving the genetic engineering of a patient's T-cells to recognize and attack cancer cells.
Chinese scientists develop new technology to decode immunotherapy resistance in tumor microenvironment
South China's Guangdong Province is accelerating its transformation into an international medical tourism hub, positioning itself as a destination for patients worldwide seeking affordable, high-quality care.
The push follows a joint initiative announced in late March by nine Chinese government departments, including the Ministry of Commerce, aimed at boosting spending by foreign tourists and enhancing exports of tourism services as part of broader efforts to expand the country's service sector.
Every day, some of the most complex surgeries are performed here. Li Zilun, deputy director of the division of vascular surgery at the First Affiliated Hospital of Sun Yat‑sen University, is among the doctors capable of carrying out these intricate procedures.
He recently completed surgery on a patient with an aortic aneurysm, a condition often described as a "time bomb" in the body’s main artery, increasingly common in aging societies around the globe. Li also specializes in highly difficult and pioneering procedures, including repairing leaks caused by failed grafts.
"This was a very challenging case. And then, we implanted the covered stent to eliminate the endoleak. Actually, the outcome was pretty good. The patient will be discharged today," said Li Zilun.
The ability to handle such complex cases -- combining international techniques with domestically produced devices -- is drawing patients from around the world to seek treatment. In addition, high safety standards and low costs are also major draws.
"Our government is encouraging innovation. So, lots of physicians -- including our vascular surgeons -- we are actively involved in the innovation that helps to increase the effectiveness and safety, and also bring down the cost," said Li.
This hospital is one of the first in Guangdong to be designated by the provincial health commission as a pilot site for building an international medical service hub.
The growing number of patients has pushed the hospital to explore new ways to transform every step -- from treatment to payment and everything in between -- into a seamless experience, reducing waiting times and delivering better care for patients.
"I think it's fast. When the patient come here for just about, I think, one week, you can solve the problem," said Xiao Haipeng, president of the First Affiliated Hospital of Sun Yat-sen University.
The hospital is also deepening its international cooperation with top-tier medical institutions, including those at Harvard University.
"Not just for China, for the whole globe, we are facing health care challenges -- emerging infectious disease and chronic, lung infectious diseases, and also the aging population, also the shortage of healthcare workforce," said Xiao.
In response to these challenges, China is promoting its own solutions, including aggressive innovation in artificial intelligence (AI)-driven workflows, while stepping up research and development investment and global engagement along the way.
"In recent years, the innovation in Western medicine is dramatically growing. An example of my hospital -- in the past few years, we have 140 innovations and seven of them are international leading innovations," said Xiao.
As global demand for medical tourism grows, China is positioning itself as a new destination. Official data shows that the number of foreign patients in Guangdong increased by 20 percent last year. Among them, the growth in inpatient admissions was even faster, rising by 76 percent.
Guangdong fast-tracks pilot for int'l medical service hub
